This is the authors' abstract. We don't add key points for this paper.
To assess the safety of sub-urothelial injection of durvalumab and examine the impact on tissue and circulating immune cell populations.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Hayne et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: